India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

America's pharmaceutical giants have been plotting to torpedo the Australia's Pharmaceuticals Benefits Scheme, despite securing major concessions 20 years ago.

Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have ...

Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...